Connect with our Cancer Team 24/7

Call us at (888) 777-4167

Global Pancreatic Cancer Research Consortium

Henry Ford leads multi-institutional consortium to advance pancreatic cancer research for early detection and new therapies.

Diagnose earlier. Live longer.

The Henry Pancreatic Cancer Center aims to do just that for patients through its global, multi-institutional research consortium which is working to discover tools for early detection and new therapies – all with the goal of reducing the pancreatic cancer mortality (death) rate and, ultimately, offering hope to more patients.

Right now, pancreatic cancer has a five-year survival rate of roughly 8 percent. With no effective screening currently available to detect pancreatic cancer early, most patients are not diagnosed until the cancer has progressed to an advanced stage.

Graphic showing phenomics, metabolomics, proteomics, transcriptomics, epigenomics, and genomics being integrated in the global consortium

Never has there been a greater opportunity for our global consortium to ‘raise the floor’ for pancreatic cancer research.

Funded by an initial $20 million gift from an anonymous individual donor, our team, led by clinical director David Kwon, M.D., and scientific director Howard Crawford, Ph.D., is working with internationally renowned partners to uncover the early warning signs and biomarkers for pancreatic cancer for earlier diagnosis and improved treatment.

Our Vision

Bring together the best minds in the world to detect pancreatic cancer earlier and help patients live longer.

Learn More

Steps to discover, develop and lead to early detection of pancreatic cancer


Graphic showing four key areas of focus. 1. Big Data - Utilize medical records to find patterns in pancreatic cancer development and outcomes. 2. Biomarkers - Employ the most innovative technologies and machine learning to understand disease. 3. Patient - Utilize patient samples to quickly translate discoveries into cancer screening and monitoring. 4. Therapy - Develop patient-specific therapy models to inform novel biomarkers for additional detection modalities.

As leaders of the consortium, Henry Ford will leverage its clinical and organizational resources to strengthen its research and partnerships, including:

  • Henry Ford Innovation Institute, which has cultivated an extensive global network, including relationships with healthcare leaders, entrepreneurs and investors in Saudi Arabia, India, and, Israel.
  • Henry Ford Cancer Institute’s Precision Medicine Program, the first and most comprehensive in Michigan to offer genomic testing and expertise of a molecular tumor board to all cancer patients.
  • Henry Ford Health System’s participation in All of Us, a National Institutes of Health Precision Medicine research program.
  • Henry Ford Health System’s Department of Public Health Sciences, which conducts and promotes population and clinical research studies to advance biomedical knowledge that will result in disease prevention and overall improved health status.

Precision Medicine

Precision Medicine works to find targeted treatments custom-fit for each person’s unique type of cancer. Discover the advances Henry Ford is bringing to all patients.

Learn More

All of Us Research Program

Henry Ford is among a few select health systems in the nation to participate in this program. We’re calling on one million people across America to help us advance how we prevent and treat diseases for generations to come.

Sign Up